Mediwound (MDWD) Receives a Buy from H.C. Wainwright

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Mediwound (MDWD), with a price target of $5.50. The company’s shares closed last Wednesday at $1.98.

According to, Ramakanth is a 2-star analyst with an average return of -0.3% and a 35.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, IntelGenx Technologies, and Corvus Pharmaceuticals.

Currently, the analyst consensus on Mediwound is a Moderate Buy with an average price target of $6.25, which is a 197.6% upside from current levels. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $7.00 price target.

See today’s analyst top recommended stocks >>

Mediwound’s market cap is currently $53.79M and has a P/E ratio of 10.90. The company has a Price to Book ratio of 3.62.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts